Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Vaccine. 2023 Jul 12;41(31):4439-4446. doi: 10.1016/j.vaccine.2023.06.029. Epub 2023 Jun 16.
This report summarizes the highlights of a workshop convened by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), on April 4-5, 2022, to provide a discussion forum for sharing insights on the current status, key challenges, and next steps to advance the current landscape of promising adjuvants in preclinical and clinical human immunodeficiency virus (HIV) vaccine studies. A key goal was to solicit and share recommendations on scientific, regulatory, and operational guidelines for bridging the gaps in rational selection, access, and formulation of clinically relevant adjuvants for HIV vaccine candidates. The NIAID Vaccine Adjuvant Program working group remains committed to accentuate promising adjuvants and nurturing collaborations between adjuvant and HIV vaccine developers.
本报告总结了美国国立过敏和传染病研究所（NIAID）、美国国立卫生研究院（NIH）于 2022 年 4 月 4 日至 5 日召开的一次研讨会的要点，该研讨会提供了一个讨论论坛，就当前有前途的佐剂在临床前和临床人类免疫缺陷病毒（HIV）疫苗研究中的现状、主要挑战和下一步进展分享见解。一个关键目标是征求和分享关于科学、监管和操作指南的建议，以弥合合理选择、获得和制定用于 HIV 候选疫苗的临床相关佐剂方面的差距。NIAID 疫苗佐剂计划工作组仍然致力于强调有前途的佐剂，并促进佐剂和 HIV 疫苗开发者之间的合作。
